Discontinued drugs in 2011: Cardiovascular drugs

Expert Opinion on Investigational Drugs

Volumn 21, Issue 10, 2012, Pages 1449-1462

  Zhao, Hong Ping ^a   Jiang, Hong Min ^a   Xiang, Bing Ren ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

ADX 415; Alipogene tiparvovec; AntihypertensivesNicOx 1; AntihypertensivesNicOx 2; Avotermin; BMS 844421; Budiodarone; Celivarone; Cinaciguat; Darexaban maleate; Flovagatran; GRNCM1; GS 9667; Letaxaban; OBE 101; PPD 10558; SB 509; Sirolimus stentJ J; Tecarfarin

Indexed keywords

ADX 415; ALIPOGENE TIPARVOVEC; AMIODARONE; ANTIHYPERTENSIVE AGENT; AVOTERMIN; AZILSARTAN MEDOXOMIL; BETAHISTINE; BMS 844421; BUDIODARONE; CARDIOVASCULAR AGENT; CELIVARONE; CINACIGUAT; CM 1; DABIGATRAN ETEXILATE; DAREXABAN; DAREXABAN MALEATE; DRONEDARONE; ENOXAPARIN; FLOVAGATRAN; GRNCM 1; GS 9667; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LETAXABAN; OBE 101; PLACEBO; PPD 10558; RAPAMYCIN; SB 509; TECARFARIN; TICAGRELOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 222714;

ACUTE CORONARY SYNDROME; ACUTE GRAFT REJECTION; ACUTE HEART FAILURE; AMYOTROPHIC LATERAL SCLEROSIS; ARTERIAL THROMBOEMBOLISM; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CONTROLLED RELEASE FORMULATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DEFIBRILLATOR; DIABETIC NEUROPATHY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FATALITY; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; DYSLIPIDEMIA; EMBRYONIC STEM CELL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERMETABOLISM; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFECTION; KIDNEY TRANSPLANTATION; LIGAMENT AND TENDON INJURY; LUNG TRANSPLANTATION; MENOPAUSE RELATED DISORDER; METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; SCAR FORMATION; SHOCK; SPINAL CORD INJURY; THROMBOEMBOLISM; THROMBOSIS; TRAUMATIC BRAIN INJURY; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; HUMANS;

EID: 84866556006     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.710198     Document Type: Review

References (42)

1. Global atlas on cardiovascular disease prevention and control. Available from: http://www.who.int/cardiovascular-diseases/en/[Last accessed 26 April 2012]
2. Cardiovascular Pharmaceutical Market Trends, 2007 to 2010. Available from: http://www.urchpublishing.com/publications/therapeutic/cardiovascular- pharmaceutical-market-trends-2007- 2010.html [Last accessed 26 April 2012]
3. Drugs, money, and glory: Is cancer beating cardiovascular disease?. Available from: http://www.theheart.org/article/1261569/print.do [Last accessed 26 April 2012]
4. Programs-GRNCM1. Available from: http://cell-therapies.geron.com/grncm1 [Last accessed 9 April 2012]
5. Geron Announces Preclinical Study Data of GRNCM1. Available from: http://ir. geron.com/phoenix.zhtml?c=67323& p=irol-newsArticle&ID= 1635737& highlight= [Last accessed 9 April 2012]
6. Geron to Focus on its Novel Cancer Programs. Available from: http://ir.geron. com/phoenix.zhtml?c=67323&p=irol-newsArticle&ID= 1635764&highlight [Last accessed 9 April 2012]
7. LATE BREAKING ABSTRACTS 70th Scientific Sessions. Available from: http://professional.diabetes.org/admin/UserFiles/file/SciSessions/ 2010%20Abstracts/2010%20ADA%20LB%20Abstracts.pdf [Last accessed 21 May 2012]
8. Annual report pursuant to section 13 and 15(d). Available from: http://www.gilead.com/AR2011/GileadSciences-10K- 20120223.pdf [Last accessed 9 April 2012]
9. Fatholahi M, Xiang Y, Wu Y, et al. A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther 2006;317:676-84
10. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549. Available from: http://www.sec.gov/Archives/edgar/data/874015/ 000110465911011094/a10-24306-110k.htm [Last accessed 21 May 2012]
11. NicOx receives e5 million milestone payment from Merck & Co. for antihypertensive collaboration. Available from: http://www.nicox.com/files/pdf/ PR2007011800EN.pdf [Last accessed 11 April 2012]
12. NicOx 2010 Financial Results. Available from: http://www.nicox.com/files/ pdf/PR2011022400EN.pdf [Last accessed 11 April 2012]
13. NicOx presents preclinical results at AHA from antihypertensive collaboration with Merck & Co., Inc. Available from: http://www.nicox.com/ files/pdf/PR2006111400EN.pdf [Last accessed 12 April 2012]
14. NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients by Merck & Co., Inc. Available from: http://www.nicox.com/files/pdf/PR2008051300EN.pdf [Last accessed 11 April 2012]
15. NicOx and Merck to broaden scope of license Agreement. Available from: http://www.nicox.com/files/pdf/PR2010091500EN.pdf [Last accessed 11 April 2012]
16. Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS). Available from: http://clinicaltrials.gov/ct2/show/NCT00748501?term=sb- 509&rank=1 [Last accessed 21 May 2012]
17. Sangamo BioSciences Announces Phase 2b Trial of SB-509 in Diabetic Neuropathy Did Not Meet Key Study Endpoints. Available from: http://investor.sangamo.com/releasedetail.cfm? ReleaseID=610157 [Last accessed 21 May 2012]
18. Furiex Announces Results for Phase II Trial of PPD-10558. Available from: http://investor.furiex.com/releasedetail.cfm?ReleaseID=631793 [Last accessed 22 May 2012]
19. Development activities. Available from: http://www.takeda.com/pdf/usr/ default/11-40972-2.pdf [Last accessed 24 May 2012]
20. Flovagatran will not be pursued. Available from: http://www.paion.de/ images/stories/investoren/finanznachrichten/2010/en/paionp101206en.pdf [Last accessed 24 May 2012]
21. ANNUAL REPORT 2010. Available from: http://www.asm2011.bayer.com/en/ bayer-annual-report-2010.pdfx [Last accessed 24 May 2012]
22. Investor Handout Meet Management. Available from: http://www.investor. bayer.com/user-upload/3763/Meet-Management-2011-Investor-Handout-Final.pdf [Last accessed 24 May 2012]
23. UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Available from: http://en.sanofi.com/Images/-20F-2011.pdf [Last accessed 24 May 2012]
24. Product Fact Sheet. Available from: http://www.aryx.com/pdf/factsheet- budiodarone.pdf [Last accessed 29 June 2012]
25. Budiodarone (ATI-2042)-Atrial Fibrillation. Available from: http://www.aryx.com/wt/page/ati2042 [Last accessed 24 May 2012]
26. Histalean achieves mixed results at Ph II. Available from: http://www. thepharmaletter.com/file/20010/histalean-achieves-mixed-results-at-ph-ii.html [Last accessed 22 May 2012]
27. Bio-Light closes obesity treatment co OBEcure [Globes, Tel Aviv, Israel]. Available from: http://www.therapeuticsdaily.com/news/article.cfm? contentValue=1979964&contentType= sentryarticle&channelID=28 [Last accessed 22 May 2012]
28. A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension. Available from: http://clinicaltrials.gov/ ct2/show/NCT00779181 [Last accessed 21 May 2012]
29. Financial Results for the First Quarter of Fiscal Year 2011(Consolidated). Available from: http://www.shionogi.co.jp/ir-en/materials/ detail/con11-08.pdf [Last accessed 9 May 2012]
30. Product Fact Sheet. Available from: http://www.aryx.com/pdf/factsheet- tecarfarin.pdf [Last accessed 29 June 2012]
31. Aryx Therapeutics' anticoagulant not superior to warfarin in Phase II/III trial; shares fall. Available from: http://www. verusmed.com/articles/view/ 60958/[Last accessed 21 May 2012]
32. Tecarfarin (ATI-5923)-Anticoagulation. Available from: http://www.aryx.com/wt/page/ati5923 [Last accessed 21 May 2012]
33. Astellas Pharma, Inc. Discontinues Development of Darexaban (YM150), an Oral Direct Factor Xa Inhibitor. Available from: http://www.astellas.com/en/ corporate/news/detail/astellas-pharmainc-discontinu.html [Last accessed 24 May 2012]
34. RISK ASSESSMENT and RISK MITIGATION REVIEW(S). Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/021560s000riskr.pdf [Last accessed 9 April 2012]
35. An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. Available from: http://clinicaltrials.gov/ct2/show/NCT01202058?term=EC09-01&rank=1 [Last accessed 9 April 2012]
36. Cordis Announces Discontinuation Of Nevo™ Sirolimus-Eluting Coronary Stent. Available from: http://www.jnj. com/connect/news/all/cordis- announcesdiscontinuation-of-nevo-sirolimus-eluting-coronary-stent [Last accessed 9 April 2012]
37. Sirolimus. Available from: http://www.nlm.nih.gov/medlineplus/druginfo/ meds/a602026.html#other-uses [Last accessed 9 April 2012]
38. Juvista in Scar Revision Surgery of Disfiguring Scars (Revise). Available from: http://clinicaltrials.gov/ct2/show/NCT00742443?term=NCT00742443&rank= 1 [Last accessed 24 May 2012]
39. Juvista EU Phase 3 trial results. Available from: http://www.renovo.com/ zh-hans/news/juvista-eu-phase-3-trial-results [Last accessed 24 May 2012]
40. RENOVO ANNOUNCES MAJOR RESTRUCTURING. Available from: http://www.renovo.com/hi/news/renovo-announces-major-restructuring [Last accessed 24 May 2012]
41. Amsterdam Molecular Therapeutics Provides Operations Update and Strategic Review of Pipeline. Available from: http://www.amtbiopharma.com/news/135/182/ Amsterdam-Molecular-Therapeutics-Provides-Operations-Update-and-Strategic- Review-of-Pipeline. html [Last accessed 21 May 2012]
42. Zhao HP, Zhang XS, Xiang BR. Discontinued drugs in 2010: cardiovascular drugs. Expert Opin Investig Drugs 2011;20:1311-25